Exposure to TNF inhibitors was linked to a reduced risk for cardiovascular events among patients with AS; the impact of IL-17 inhibitors was less clear.

Treatment with TNF inhibitors yielded no differences in outcomes vs. other antirheumatic therapies among U.S. veterans with ...

TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) ("TNF" or the "Company"), a clinical stage biopharmaceutical company committed to ...

3 TNF inhibitor drug category: the global market value for TNF inhibitors was estimated to be $39.7 billion in 2024. Growing at an expected CAGR of 3.6% for the next five years, the TNF inhibitor ...

Thus, as with any new treatment modality, caution is required in the follow-up of patients receiving TNF blocker treatment, since new side effects and complications are continuously being reported.

After combing through 4,000 existing medications, an artificial intelligence tool helped uncover one that saved the life of a ...

The most important determinant for beginning TNF-blocker therapy was considered to be disease activity and severity. There is debate on the efficacy of low-dose infliximab regime in AS.

TNF Pharmaceuticals (TNFA) announced that it has achieved a safety data milestone supporting expanded and longer-term clinical studies of its ...

today announced that it has initiated the first in a series of studies to evaluate the impact of its novel oral TNF-alpha (TNF-α) inhibitor drug, isomyosamine, in preserving lean muscle mass during ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Worries that ...